Medications to Manage Constipation on Zepbound (tirzepatide): First-Line and Beyond

At a glance

• Incidence in trials: Constipation occurred in 6% to 11% of patients on tirzepatide across the SURMOUNT program, compared to 1% to 4% on placebo.
• Typical onset: Most cases begin within the first 4 to 8 weeks, often coinciding with dose escalation from 5 mg to 10 mg or higher.
• Mechanism: Tirzepatide activates both GLP-1 and GIP receptors, slowing gastric emptying and colonic transit time.
• First-line management: Osmotic laxative (PEG 3350 to 17 g daily) plus hydration.
• When to escalate: No bowel movement for 3+ days despite OTC therapy, abdominal pain, rectal bleeding, or new-onset vomiting.
• When to consider discontinuation: Fecal impaction, bowel obstruction signs, or constipation refractory to prescription therapy after discussion with the prescribing clinician.

Why Zepbound Causes Constipation

Tirzepatide is a dual GIP/GLP-1 receptor agonist. The GLP-1 component reduces the rate at which the stomach empties its contents into the small intestine, a property the FDA label quantifies as a clinically meaningful delay in gastric emptying. That same signaling cascade extends to the colon. Slowed colonic transit allows the intestinal lining to reabsorb more water from stool, producing harder, less frequent bowel movements.

The effect is dose-dependent. In SURMOUNT-1, constipation rates rose from 6.0% at the 5 mg dose to 11.1% at 15 mg, while placebo participants reported a rate of just 2.7%. SURMOUNT-2 data in patients with type 2 diabetes confirmed a similar pattern, with 5.9% to 7.2% of participants reporting constipation. Most episodes are mild to moderate. Fewer than 1% of trial participants discontinued tirzepatide specifically because of constipation.

First-Line: Osmotic Laxatives

The American Gastroenterological Association (AGA) recommends osmotic laxatives as first-line pharmacotherapy for chronic constipation. Polyethylene glycol 3350 (PEG 3350, sold as MiraLAX or generic equivalents) is the most studied option.

PEG 3350 (MiraLAX)

• Dose: 17 g (one capful) dissolved in 8 oz of liquid, once daily.
• Onset: 24 to 72 hours for the first effective bowel movement.
• Can be titrated up to 34 g daily if needed, though most patients respond to the standard dose.
• Does not cause electrolyte shifts at standard doses in adults with normal kidney function.

Lactulose

• Dose: 15 to 30 mL (10 to 20 g) once or twice daily.
• A reasonable alternative when PEG 3350 is unavailable. Fermentation in the colon can produce gas and bloating, which may compound the GI discomfort tirzepatide already causes.

Magnesium-based options (Milk of Magnesia)

• Dose: 15 to 30 mL of magnesium hydroxide once daily at bedtime.
• Effective and inexpensive. Use with caution in patients with renal impairment due to risk of hypermagnesemia.

Start PEG 3350 as the default. Give it 5 to 7 days of consistent daily use before judging whether it is working.

Second-Line: Stimulant Laxatives

When an osmotic agent alone is not enough, adding a stimulant laxative is appropriate. The ACG clinical guideline on management of chronic idiopathic constipation supports their use as adjunctive therapy.

Bisacodyl (Dulcolax)

• Dose: 5 to 10 mg orally at bedtime, or 10 mg rectally as a suppository.
• Produces a bowel movement within 6 to 12 hours when taken by mouth, or 15 to 60 minutes as a suppository.
• Best used on an as-needed basis (2 to 3 times per week) rather than daily.

Sennosides (Senna, Senokot)

• Dose: 8.6 to 17.2 mg at bedtime. Maximum 34.4 mg daily.
• Onset: 6 to 12 hours.
• Can be combined with PEG 3350 safely. Prolonged daily use beyond 1 to 2 weeks should prompt a conversation about escalating to prescription therapy.

Avoid relying on stimulant laxatives as your sole treatment for more than two consecutive weeks without medical reassessment. They work well as rescue therapy on top of a standing osmotic regimen.

Prescription Options for Refractory Constipation

If constipation persists despite 2 to 4 weeks of optimized OTC therapy, prescription agents are indicated. These drugs increase intestinal fluid secretion or directly stimulate colonic motility through mechanisms independent of the GLP-1 pathway.

Linaclotide (Linzess)

• Dose: 145 mcg once daily on an empty stomach, at least 30 minutes before the first meal.
• FDA-approved for chronic idiopathic constipation (CIC). A 72 mcg dose is also available for IBS-C.
• Mechanism: activates guanylate cyclase-C receptors on the intestinal epithelium, increasing chloride and water secretion into the lumen.
• Common side effect: diarrhea (reported in about 16% of CIC patients in trials). Start at the lower dose if the patient is concerned about overcorrection.

Lubiprostone (Amitiza)

• Dose: 24 mcg twice daily with food.
• Approved for CIC in adults. Also has an indication for opioid-induced constipation at 24 mcg twice daily.
• Nausea is the most common side effect (up to 29%), which may compound tirzepatide-related nausea during dose titration.

Prucalopride (Motegrity)

• Dose: 2 mg once daily. Reduce to 1 mg daily in patients with severe renal impairment (CrCl <30 mL/min).
• A selective 5-HT4 receptor agonist that directly stimulates colonic motility. Works through a different pathway than osmotic or secretory agents.
• Useful when the patient has slow-transit constipation confirmed on testing or has not responded to secretagogues.

What About Fiber Supplements?

Bulk-forming agents (psyllium, methylcellulose, wheat dextrin) are a common first recommendation for general constipation. On tirzepatide, the situation is different. Because tirzepatide delays gastric emptying significantly, adding fiber on top of an already slow gut can worsen bloating, gas, and abdominal distension. Patients on GLP-1 agonists frequently report that fiber supplements made their symptoms worse before they got better.

If a patient wants to use fiber, soluble fiber (psyllium) is preferable to insoluble forms. Start at half the recommended dose and titrate slowly. But in the acute phase of GLP-1-related constipation, PEG 3350 is a better starting point. Fiber works best once the patient has stabilized on a maintenance tirzepatide dose and their gut motility has partially adapted.

Drug Interactions to Watch

Tirzepatide's effect on gastric emptying can alter the absorption of oral medications that depend on rapid gastric transit. The FDA prescribing information specifically notes this concern for oral contraceptives and recommends switching to a non-oral contraceptive method or adding a barrier method for 4 weeks after initiation and after each dose increase.

For laxatives, the interaction risk is low because most laxatives act in the colon, well past the point of gastric emptying delay. One notable exception: oral bisacodyl tablets have an enteric coating designed to dissolve in the small intestine. Delayed gastric emptying could theoretically alter the timing (though not the efficacy) of bisacodyl's action. If predictable timing matters, the rectal suppository form avoids this entirely.

Patients taking levothyroxine, warfarin, or digoxin should discuss timing with their pharmacist, as these narrow-therapeutic-index drugs may have altered absorption kinetics during the first weeks on tirzepatide or after dose changes.

When to Escalate

Contact the prescribing clinician if any of the following occur:

• No bowel movement for 4 or more consecutive days despite OTC laxatives
• New-onset abdominal distension with vomiting (possible obstruction)
• Rectal bleeding or new onset of thin, ribbon-like stools
• Severe abdominal pain that is worsening rather than improving
• Signs of fecal impaction (constant urge to defecate with inability to pass stool, overflow liquid stool around a hard mass)

Dose reduction of tirzepatide (stepping back from 15 mg to 10 mg, for example) can also improve constipation. The SURMOUNT-4 trial demonstrated that GI side effects were most prominent during active dose escalation and tended to plateau or improve once patients reached a stable maintenance dose.

Frequently asked questions

›How common is constipation on Zepbound?

Across the SURMOUNT trials, 6% to 11% of patients on tirzepatide reported constipation, depending on the dose. It was more common at the 10 mg and 15 mg doses than at 5 mg. Most cases were rated mild to moderate by investigators.

›Can I take MiraLAX every day while on Zepbound?

Yes. PEG 3350 (MiraLAX) is safe for daily use in adults with normal kidney function. It is the recommended first-line agent for GLP-1-associated constipation. Give it at least 5 to 7 days before deciding it is not working.

›Should I take fiber supplements for constipation on tirzepatide?

Fiber is not the best first choice while on tirzepatide. Delayed gastric emptying can make fiber-related bloating worse. Start with PEG 3350 instead. If you want to add fiber later, use soluble fiber (psyllium) at a low dose and increase gradually.

›Is it safe to use Dulcolax with Zepbound?

Yes. Bisacodyl (Dulcolax) can be used alongside tirzepatide. Use it as a rescue option 2 to 3 times per week, not as a daily standing regimen. The suppository form provides more predictable timing because it bypasses the stomach.

›When should I ask my doctor about prescription constipation medication?

If 2 to 4 weeks of daily PEG 3350 plus as-needed stimulant laxatives have not resolved your symptoms, it is time to discuss linaclotide (Linzess), lubiprostone (Amitiza), or prucalopride (Motegrity) with your provider.

›Does constipation from Zepbound go away over time?

For many patients, yes. GI side effects are most pronounced during dose escalation. Once the body adjusts to a stable maintenance dose, colonic transit often partially recovers. Some patients need ongoing laxative support throughout treatment.

›Will lowering my Zepbound dose help with constipation?

Constipation in the SURMOUNT trials was dose-dependent. Stepping back from 15 mg to 10 mg, or from 10 mg to 5 mg, can reduce GI symptoms. Discuss dose adjustment with your prescriber before making changes.

›Can constipation on Zepbound cause a bowel obstruction?

Bowel obstruction from GLP-1 agonist constipation is rare but has been reported in post-marketing surveillance. Warning signs include vomiting, inability to pass gas, severe distension, and escalating abdominal pain. Seek emergency care if you experience these.

›Does Zepbound interact with my other oral medications?

Tirzepatide slows gastric emptying, which can affect absorption timing for oral drugs. This is most relevant for narrow-therapeutic-index medications like levothyroxine, warfarin, and oral contraceptives. Talk to your pharmacist about spacing or monitoring.

›Is stool softener (docusate) enough for Zepbound constipation?

Docusate sodium (Colace) alone is unlikely to be sufficient. Clinical evidence for docusate as a standalone laxative is weak. It may be used as an add-on to PEG 3350, but it should not replace an osmotic laxative as primary therapy.

References

1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
2. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01200-X/fulltext
3. Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA. 2024;331(1):38-48. https://jamanetwork.com/journals/jama/fullarticle/2812936
4. Zepbound (tirzepatide) prescribing information. Eli Lilly and Company. U.S. Food and Drug Administration. 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf
5. American Gastroenterological Association. AGA technical review on constipation. Gastroenterology. 2013;144(1):218-238. https://www.gastrojournal.org/article/S0016-5085(12)01545-4/fulltext
6. Ford AC, Moayyedi P, Lacy BE, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014;109(Suppl 1):S2-S26. https://journals.lww.com/ajg/fulltext/2014/08000/an_evidence_based_approach_to_the_management_of.10.aspx
7. Linzess (linaclotide) prescribing information. Allergan. U.S. Food and Drug Administration. 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202811s013lbl.pdf
8. Amitiza (lubiprostone) prescribing information. Sucampo/Takeda. U.S. Food and Drug Administration. 2012. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021908s011lbl.pdf
9. Camilleri M, Piessevaux H, Yiannakou Y, et al. Efficacy and safety of prucalopride in chronic constipation: an integrated analysis of six randomized, controlled clinical trials. Dig Dis Sci. 2016;61(8):2357-2372. https://pubmed.ncbi.nlm.nih.gov/30661054/
10. Xing JH, Soffer EE. Adverse effects of laxatives. Dis Colon Rectum. 2001;44(8):1201-1209. https://pubmed.ncbi.nlm.nih.gov/15654804/